Products + Solutions

Drugs + Biologics

Several SRI drug candidates are available for partnering. SRI owns the intellectual property surrounding these compounds.

Technologies for License

researcher working in lab
SR16157: A Safer, More Effective Estrogen Inhibitor for Treating Breast Cancer

As an alternative to AIs, SRI has developed an estrogen inhibitor called SR16157. This rationally designed drug achieves more complete estrogen suppression by inhibiting estrogen in two ways.

researchers in lab coats working at a lab table
SR16388: A Novel Drug That Inhibits Tumor Growth by Targeting ERRalpha

SRI researchers have developed a novel steroidal compound, SR16388, which very selectively binds to and inhibits ERRalpha. This drug also regulates tumor energy metabolism by strongly inhibiting the protein HIF-1alpha, which promotes tumor cell survival in low-oxygen conditions.

two researchers in lab coats working at equipment
TAS-108: A Better Anti-Estrogen Drug for Treating Breast Cancer

As a safer and more effective alternative to currently available drugs, SRI researchers have developed TAS-108, an oral anti-estrogen drug for the treatment of advanced breast cancer.

Next Steps